Mind Medicine, a Canadian pharmaceutical firm, wants to create medications from LSD, ibogaine, and possibly other psychedelic drugs, too. And if all goes according to plan, the public can soon buy a piece of the company, as well.
The Canadian Stock Exchange has become a haven for licensed weed companies that can’t yet list on the US exchange due to America’s federal pot prohibition. But pharmaceutical psychedelics may soon be joining our favorite flower for infusions of public investments.
Mind Medicine, Inc., a Canadian biotech firm, is entering Phase II clinical trials for two experimental treatments. According to its website, one trial involves an ibogaine-derived drug for treating opioid addiction. The other trial will test LSD...
Read the full article @ Merry Jane